Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Eribulin|DRUG: Tislelizumab
Sponsor: Fudan University